Biocon Pharma, a subsidiary of Biocon, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Dapagliflozin Tablets in 5 mg and 10 mg dosages. This medication is indicated for adults with type 2 diabetes mellitus, serving as an adjunct to diet and exercise to improve glycemic control and reduce the risk of hospitalization for heart failure in patients with established cardiovascular disease or multiple cardiovascular risk factors. This FDA approval strengthens Biocon's diabetes portfolio, which includes oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, demonstrating the company's commitment to meeting the evolving needs of individuals living with diabetes worldwide. The Dapagliflozin Tablets will be produced at Biocon's FDA-approved manufacturing facilities, ensuring compliance with global quality and regulatory standards.